ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

GSK at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

GSK takes part in 4 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1023. Its program centres on treatment and survival in endometrial and ovarian cancers, alongside drug discovery. It covers long-term survival and a drug designed to target multiple mutations in gastrointestinal stromal tumours.

OrganizationESMO 2026 Attendance
Large pharmaExhibitor
British pharmaceutical company whose oncology medicines include niraparib, dostarlimab and momelotinib.
Booth
Exhibiting at Booth 1023
Satellite
Fri Oct 23
18:15–19:45
GSK - From evidence to clinical practice: Long-term survival outcomes in advanced endometrial cancer
Sponsored session · with NYU Langone Perlmutter Cancer Center
Gynaecological cancers
Satellite
Sat Oct 24
13:00–14:30
GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care
Sponsored session · with Hospital Universitario Puerta de Hierro Majadahonda
Gynaecological cancers
Talk
Mon Oct 26
11:05–11:30
Digital biology twins and predictive oncology in drug discovery and development
Digital health and AI in oncology: Transforming patient monitoring and care

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at GSK

Tell us what you sell and we’ll find the people at GSK most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction